Artelo Biosciences (ARTL) Change in Cash (2014 - 2025)
Artelo Biosciences (ARTL) posted quarterly Change in Cash of -$1.1 million for Q4 2025, up 44.53% year-over-year from -$774941.7 in Q4 2024, and down 223.7% quarter-over-quarter from -$346000.0 in Q3 2025.
Artelo Biosciences (ARTL) Change in Cash (2014 - 2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported Change in Cash for 12 consecutive years, with -$1.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Cash rose 44.53% year-over-year to -$1.1 million; the TTM figure through Dec 2025 stood at -$1.7 million (down 264.36% YoY), while the FY2025 annual figure was -$1.7 million, down 264.36% from the prior year.
- Change in Cash retreated to -$1.1 million in Q4 2025 per ARTL's latest filing, from -$346000.0 in the prior quarter.
- Across five years, Change in Cash topped out at $7.4 million in Q4 2021 and bottomed at -$5.0 million in Q3 2022.
- Historically, Change in Cash has averaged -$45924.5 across 5 years, with a median of -$330000.0 in 2024.
- Annual changes were most pronounced in 2024 — Change in Cash tumbled 5885.71% — and 2025, when it surged 520.38%.
- Artelo Biosciences' Change in Cash stood at $7.4 million in 2021, then plunged by 103.34% to -$248000.0 in 2022, then surged by 170.97% to $176000.0 in 2023, then plunged by 1247.16% to -$2.0 million in 2024, then surged by 44.53% to -$1.1 million in 2025.
- Business Quant data shows ARTL's Change in Cash at -$1.1 million in Q4 2025, -$346000.0 in Q3 2025, and $1.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Artelo Biosciences | 107,735.40 | -492,264.60 | - | -1.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.12 Mn |
| Sep 30, 2025 | -346,000.00 |
| Jun 30, 2025 | 1.32 Mn |
| Mar 31, 2025 | -1.59 Mn |
| Dec 31, 2024 | -2.02 Mn |
| Sep 30, 2024 | 3.48 Mn |
| Jun 30, 2024 | -314,000.00 |
| Mar 31, 2024 | -1.62 Mn |
| Dec 31, 2023 | 176,000.00 |
| Sep 30, 2023 | -3.08 Mn |
| Jun 30, 2023 | -1.20 Mn |
| Mar 31, 2023 | 28,000.00 |
| Dec 31, 2022 | -248,000.00 |
| Sep 30, 2022 | -4.99 Mn |
| Jun 30, 2022 | 1.77 Mn |
| Mar 31, 2022 | -1.81 Mn |
| Nov 30, 2021 | 7.42 Mn |
| Feb 28, 2021 | 3.32 Mn |
| Nov 30, 2020 | 5.25 Mn |
| Aug 31, 2020 | 862,709.00 |